Mostrar el registro sencillo del ítem

Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis

dc.rights.licenseopenen_US
dc.contributor.authorSOLE, Guilhem
dc.contributor.authorMATHIS, Stephane
dc.contributor.authorFRIEDMAN, Diane
dc.contributor.authorSALORT-CAMPANA, Emmanuelle
dc.contributor.authorTARD, Celine
dc.contributor.authorBOUHOUR, Francoise
dc.contributor.authorMAGOT, Armelle
dc.contributor.authorANNANE, Djillali
dc.contributor.authorCLAIR, Bernard
dc.contributor.authorLE MASSON, Gwendal
dc.contributor.authorSOULAGES, Antoine
dc.contributor.authorDUVAL, Fanny
dc.contributor.authorCARLA, Louis
dc.contributor.authorVIOLLEAU, Marie-Helene
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAULNIER, Tiphaine
ORCID: 0000-0001-8551-4200
dc.contributor.authorSEGOVIA-KUENY, Sandrine
dc.contributor.authorKERN, Lea
dc.contributor.authorANTOINE, Jean-Christophe
dc.contributor.authorBEAUDONNET, Guillemette
dc.contributor.authorAUDIC, Frederique
dc.contributor.authorKREMER, Laurent
dc.contributor.authorCHANSON, Jean-Baptiste
dc.contributor.authorNADAJ-PAKLEZA, Aleksandra
dc.contributor.authorSTOJKOVIC, Tanya
dc.contributor.authorCINTAS, Pascal
dc.contributor.authorSPINAZZI, Marco
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
dc.contributor.authorATTARIAN, Shahram
dc.date.accessioned2021-04-07T09:45:02Z
dc.date.available2021-04-07T09:45:02Z
dc.date.issued2021-02-10
dc.identifier.issn0028-3878en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26883
dc.description.abstractEnOBJECTIVE: To describe the clinical characteristics and outcomes of COVID-19 among patients with MG and identify factors associated with COVID-19 severity in MG patients. METHODS: The CO-MY-COVID registry was a multicenter, retrospective, observational cohort study conducted in neuromuscular referral centers and general hospitals of the FILNEMUS network (between March 1, 2020, and June 8, 2020), including MG patients with a confirmed or highly-suspected diagnosis of COVID-19. COVID-19 was diagnosed based on a polymerase chain reaction (PCR) test from a nasopharyngeal swab and/or SARS-CoV-2 serology, thoracic computed tomography (CT-scan), or typical symptoms. The main outcome was COVID-19 severity based on location of treatment/management (home, hospitalized in a medical unit, or in an intensive care unit). We collected information on demographic variables, general history, and risk factors for severe COVID-19. Multivariate ordinal regression models were used to identify factors associated with severe COVID-19 outcomes. RESULTS: Among 3,558 MG patients registered in the French database for rare disorders, 34 (0.96%) had COVID-19. The mean age at COVID-19 onset was 55.0 ±19.9 years (mean MG duration: 8.5 ± 8.5 years). By the end of the study period, 28 patients recovered from COVID-19, 1 remained affected, and 5 died. Only high Myasthenia Gravis Foundation of America (MGFA) class (≥IV) before COVID-19 was associated with severe COVID-19 (p=0.004); factors that were not associated included gender, MG duration, and medium MGFA classes (≤IIIb). The type of MG treatment had no independent effect on COVID-19 severity. CONCLUSIONS: This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes. However, the risk of severe COVID-19 is elevated in patients with high MGFA classes [odds ratio: 102.6 (4.4; 2,371.9)]. These results are important for establishing evidence-based guidelines for the management of MG patients during the COVID-19 pandemic.
dc.language.isoENen_US
dc.subject.enCOVID-19
dc.subject.enCorticosteroids
dc.subject.enImmunosuppressant
dc.subject.enMyasthenia gravis
dc.subject.enPrognosis
dc.subject.enRisk factors
dc.title.enImpact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis
dc.title.alternativeNeurologyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1212/wnl.0000000000011669en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33568541en_US
bordeaux.journalNeurologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERM
bordeaux.teamSEPIAen_US
bordeaux.teamBIOSTAT_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03191551
hal.version1
hal.date.transferred2021-04-07T09:45:08Z
hal.audienceInternationale
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2021-02-10&rft.eissn=0028-3878&rft.issn=0028-3878&rft.au=SOLE,%20Guilhem&MATHIS,%20Stephane&FRIEDMAN,%20Diane&SALORT-CAMPANA,%20Emmanuelle&TARD,%20Celine&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem